Evidence map›Paper›PMID 42331775›Full record

ArticleBlood cancer journal2026

Rovadicitinib, a first-in-class JAK/ROCK inhibitor, in patients with myelofibrosis: a preclinical and phase I study.

Zefeng Xu, Jinqin Liu, Zhenya Hong, Qingsong Yin, Xuelan Zuo, Qin Wen, Lihong Li, Chunkang Chang, Xin Du, Yiran Wang and 5 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Zefeng Xu *MDS and MPN Center, Blood Disease Hospital and Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, China.ORCID http://orcid.org/0009-0001-0147-2291
Jinqin Liu *MDS and MPN Center, Blood Disease Hospital and Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, China.
Zhenya HongDepartment of Hematology, Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Qingsong YinDepartment of Hematology, Henan Cancer Hospital‌, Zhengzhou, China.
Xuelan ZuoDepartment of Hematology, Zhongnan Hospital of Wuhan University‌, Wuhan, China.
Qin WenDepartment of Hematology, Xinqiao Hospital ARMY Medical University, Chongqing, China.
Lihong LiDepartment of Hematology, Beijing Tsinghua Changgung Hospital, Beijing, China.
Chunkang ChangDepartment of Hematology, Shanghai Sixth People's Hospital, Shanghai, China.
Xin DuDepartment of Hematology, Guangdong General Hospital (Guangdong Academy of Medical Sciences), Guangzhou, China.
Yiran WangDepartment of Clinical Medicine, CHIA TAI Tianqing Pharmaceutical Group Co. Ltd. Research Institute, Nanjing, China.
Xiaoming YangClinical Biostatistics Department, CHIA TAI Tianqing Pharmaceutical Group Co. Ltd. Research Institute, Nanjing, China.
Chenxiao YangClinical Biostatistics Department, CHIA TAI Tianqing Pharmaceutical Group Co. Ltd. Research Institute, Nanjing, China.
Haifei JiaClinical Operations Department, CHIA TAI Tianqing Pharmaceutical Group Co. Ltd. Research Institute, Nanjing, China.
Ling PanDepartment of Hematology, West China Hospital of Sichuan University, Chengdu, China. lingpan20002000@aliyun.com.
Zhijian XiaoMDS and MPN Center, Blood Disease Hospital and Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, China. zjxiao@ihcams.ac.cn.ORCID http://orcid.org/0000-0002-1099-4489

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42331775
PMCPMC13287751

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.